Literature DB >> 9251696

Glycohaemoglobin: a crucial measurement in modern diabetes management. Progress towards standardisation and improved precision of measurement. Australian Diabetes Society, the Royal College of Pathologists of Australasia and the Australasian Association of Clinical Biochemists [consensus development conference].

P G Colman1, G I Goodall, P Garcia-Webb, P F Williams, M E Dunlop.   

Abstract

There are currently four principal glycohaemoglobin assay techniques (ion-exchange chromatography, electrophoresis, affinity chromatography and immunoassay) and about 20 different methods that measure different glycated products and report different units. Standardisation will lead to all assays reporting results in a standard unit, the HbA1c percentage of total serum haemoglobin, and should be in place within the next one to three years. In the interim, clinicians using glycohaemoglobin assays should be aware that the ranges indicating good and poor glycaemic control can vary markedly between different assays. The reproducibility of some assays may be insufficient to provide definitive evidence of changes in glycaemic control. Some assays may be so imprecise that they are unable to separate patients with good and poor control. INTERIM RECOMMENDATIONS 1 The terminology to be used for the assay is glycohaemoglobin (GHb) assay (recommendation from the combined meetings of the International Federation of Clinical Chemistry [IFCC] Working Group on HbA1c standardisation and the American Association of Clinical Chemistry [AACC] Subcommittee on Glycohemoglobin). 2 The unit of measurement for GHb assays should be reported as %HbA1c (Diabetes Control and Complications Trial equivalent). 3 Other units, such as % total GHb or %HbA1, should not be used. Assays producing these units should be converted to %HbA1c reporting units. 4 Assays with high precision are highly desirable. The IFCC/AACC are currently recommending between-run coefficients of variation of less than 5% for manufacturers of kits and instruments. However, between-run coefficients of variation of less than 3% are far more clinically useful and therefore desirable.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9251696     DOI: 10.5694/j.1326-5377.1997.tb138790.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  8 in total

1.  The analytical quality of point-of-care testing in the 'QAAMS' model for diabetes management in Australian aboriginal medical services.

Authors:  Mark D S Shephard; Janice P Gill
Journal:  Clin Biochem Rev       Date:  2006-11

2.  Uncertainty of measurement in quantitative medical testing: a laboratory implementation guide.

Authors:  G H White; I Farrance
Journal:  Clin Biochem Rev       Date:  2004

3.  Results of an innovative education, training and quality assurance program for point-of-care HbA1c testing using the Bayer DCA 2000 in Australian Aboriginal Community Controlled Health Services.

Authors:  Mark D Shephard; Janice P Gill
Journal:  Clin Biochem Rev       Date:  2003-11

4.  Proceedings of the 10th Asian Pacific Congress of Clinical Biochemistry in conjunction with the Australasian Association of Clinical Biochemists' 42nd Annual Scientific Conference.

Authors: 
Journal:  Clin Biochem Rev       Date:  2004

Review 5.  Different intensities of glycaemic control for pregnant women with pre-existing diabetes.

Authors:  Philippa Middleton; Caroline A Crowther; Lucy Simmonds
Journal:  Cochrane Database Syst Rev       Date:  2016-05-04

6.  HbA1c standardisation destination--global IFCC Standardisation. How, why, where and when--a tortuous pathway from kit manufacturers, via inter-laboratory lyophilized and whole blood comparisons to designated national comparison schemes.

Authors:  Ian Goodall
Journal:  Clin Biochem Rev       Date:  2005-02

Review 7.  Different intensities of glycaemic control for pregnant women with pre-existing diabetes.

Authors:  Philippa Middleton; Caroline A Crowther; Lucy Simmonds
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

8.  Use of a reference four-component model to define the effects of insulin treatment on body composition in type 2 diabetes: the 'Darwin study'.

Authors:  I C Packianathan; N J Fuller; D B Peterson; A Wright; W A Coward; N Finer
Journal:  Diabetologia       Date:  2005-02-02       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.